Clinical Research Directory
Browse clinical research sites, groups, and studies.
Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
Sponsor: Guangdong Provincial People's Hospital
Summary
EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT) remains unclear. This retrospective study examines the association between RVT and survival outcomes. The findings will further validate the importance of RVT as a surrogate.
Official title: Association Between Residual Viable Tumor and Prognosis After Neoadjuvant Targeted Therapy in EGFR-Mutated Non-small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
120
Start Date
2025-02-01
Completion Date
2025-12-30
Last Updated
2025-02-21
Healthy Volunteers
No
Conditions
Locations (1)
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China